Eph receptors are the largest family of tyrosine kinases first identified in the erythropoietin-producing hepatocellular (Eph) carcinoma cell line in 1987 by Hirai and colleagues [1] , while their cognate ligands, the eph receptor interacting proteins, were termed ephrin molecules (also designated as Efn molecules) [2] . There are sixteen Eph receptors (EphA1-A10 and EphB1-B6) and nine ephrin ligands (ephrinA1-A6 and ephrinB1-B3) [2, 3] (Fig. 1) . The receptors are divided into the A or B subclasses based on their binding affinity for their respective ligands. The structural homology is maintained between the Eph receptors of both subclasses; they are composed of extracellular and cytoplasmic components [2] . The extracellular portion of the Eph receptor consists of an amino terminal ligand binding domain, a cysteine-rich region and two fibronectin type III repeats [4] . The cytoplasmic region of the Eph receptor contains SRC homology 2 binding sites, a juxtamembrane region, a tyrosine kinase domain, a sterile alpha motif (SAM) protein-protein interaction domain, and a post-synaptic density, disc large, zona occludens-1 (PDZ) binding motif [5] . Each region is important in activating various signalling cascades and mediating a number of downstream events including cell shape, attachment, migration, proliferation, differentiation [6] [7] [8] [9] . The Eph receptors signal and mediate these responses through tyrosine phosphorylation and protein-protein interactions. Binding of the ephrin ligand to the globular domain of the Eph receptor causes the autophosphorylation of the two kinases within the juxtamembrane domain, resulting in a conformational change of the juxtamembrane domain, exposing the kinases of the intracellular tyrosine kinase domain and converting it to an "active form" that can activate or repress downstream signalling cascades. Conversely, protein-protein interactions within the SAM domain Abstract Bone marrow mesenchymal stromal/stem cells (BMSC) are fundamental regulatory elements of the hematopoietic stem cell niche; however, the molecular signals that mediate BMSC support of hematopoiesis are poorly understood. Recent studies indicate that BMSC and hematopoietic stem/progenitors cells differentially express the Eph cell surface tyrosine kinase receptors, and their ephrin ligands. Eph/ephrin interactions are thought to mediate cross-talk between BMSC and different hematopoietic cell populations to influence cell development, migration and function. This review summarizes Eph/ephrin interactions in the regulation of BMSC communication with hematopoietic stem/progenitor cells and discusses Eph/ephrintargeted therapeutic strategies that are currently being pursued for various hematotological malignancies.
and PDZ domain at the carboxyl terminus of the receptor can function independently of kinase phosphorylation [10] .
The ephrin ligands are sub-divided into two groups based on their structure, the ephrin-A and ephrin-B [11] . The ephrin-A ligands are GPI linked to the membrane, where the GPI anchor is composed of one molecule of phosphatidylinositol, which has a carbohydrate chain link through the C-6 hydroxyl of the inositol. The GPI anchor functions to attach the ephrin-A ligand to the exoplasmic leaflet of the membrane and to other specific domains inside the cell [10] . Conversely, ephrin-B ligands are transmembrane proteins with a short cytoplasmic tail, which contains functional tyrosine kinase phosphorylation sites and an intracellular PDZ binding motif [12] .
The Eph family of molecules is unique in that both the Eph receptor and ephrin ligand can act as either a receptor or a ligand, and in many situations, they can also act as both [13] . Forward signalling is mediated through the Eph receptor, whereas reverse signalling is mediated through ephrin ligand [10] . Bi-directional signalling involves the simultaneous activation of both the Eph receptor and the ephrin ligand upon Eph/ephrin binding and initiates downstream signalling pathways into the respective Eph and ephrin expressing cells [13] . The unique characteristic of the Eph/ephrin family is their binding ability. The receptors and ligands of both subclasses bind with varying affinity and promiscuity within each subclass and limited binding between subclasses [2, 14] (Fig. 2) . Eph/ephrin molecules function through cell to cell interactions [2] where their signalling is crucial in developmental cell positioning [15] , tissue and organ patterning [16] , post-natal stem cell niche maintenance within the brain, intestine, skin, skeletal muscle, tooth [9, 14, 17] , bone [7, 8, 18] and hematopoietic tissues [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] .
Eph and ephrin molecules expressed by hematopoietic stem/progenitor cells
Human haematopoietic stem cells (HSC) are identified by the lack of cell surface markers that are normally present on lineage committed hematopoietic cells, while still expressing specific antigens such as CD34 that assist in the isolation of purified HSC [29] . Primitive human HSC (CD34
) are a highly enriched population capable of repopulating the hematopoietic system of SCID and NOD-SCID mice [30] . In the adult mouse, repopulating HSC are also defined by the lack of cell surface markers that are normally present on lineage committed cells, while still expressing high levels of stem cell-antigen-1 (Sca1 + ), stem cell factor ligand, c-Kit + , and signalling lymphocytic activation molecule, CD150
+ , but lacking CD48 expression [31] [32] [33] [34] . Whilst the Eph receptor tyrosine kinase family was first identified in the hematopoietic system, it has only really been in the last decade that they have been interrogated for their potential role in hematopoietic stem/progenitor cell development and function, both in humans and mice [19, 21, 24, 26, 27] .
Various Eph and ephrin molecules of both subclasses have been detected on human and mouse myeloid, erythroid, lymphoid populations and platelets [19, 22, 23, 25, 27, 35, 36] . These molecules have been implicated in a number of processes relating to progenitor cell adhesion, migration, differentiation [23, 27] , co-stimulation of T cell receptor Fig. 1 The structure of the Eph receptors and their ephrin binding ligands. Eph receptors are transmembrane proteins, consisting of a cysteine-rich region, fibronectin type III repeats, juxtamembrane, kinase, SAM and PDZ binding motif domains. The ephrin-B ligands are also transmembrane proteins while the ephrin-A ligands are GPI-anchor proteins. Forward signalling is through the cell expressing the Eph receptor whereas reverse signalling is via the cell expressing the ephrin ligand. GPI glycosyl phosphatidylino-sitol, PDZ post-synaptic density, disc large, zona occludens-1, FNIII fibronectin III, SAM sterile alpha motif complex [37] [38] [39] , B-cells communication to dendritic cells [40] , and platelet activation and aggregation [41] . Other studies have reported the expression of different Eph and ephrin molecules by both human and mouse hematopoietic progenitor cell populations (Table 1) . Gene expression analyses have identified high expression levels of EphA1, ephrin-A2, ephrin-A3 and ephrin-B2 by purified human bone marrow CD34 + HSC [42] [43] [44] , whereas protein analyses demonstrated EphA2 and EphB2 expression on human mobilized peripheral blood CD34 + HSC [20] . Furthermore, EphB4 has been detected on human HSC isolated from umbilical cord blood using flow cytometric analysis [27] . In mouse studies, EphA1-EphA5 and ephrin-A1-ephrin-A5 were shown to be expressed by hematopoietic progenitor cells isolated from the bone marrow using flow cytometric analysis and quantitative real-time PCR [26] . From these findings, it appears that Eph/ephrin expression varies on different hematopoietic stem/progenitor cell populations depending on location, differentiation state and tissue source. However, the functional consequences of differential Eph/ephrin expression have yet to be determined.
Eph and ephrin molecules expressed by bone marrow stem/stromal cells
Human BMSC are a non-hematopoietic adult multipotent stem cell clonogenic population defined by the immunophe- [45] [46] [47] [48] that have the capacity to differentiate into osteoblasts, adipocytes, and chondrocytes and reconstitute a hematopoietic microenvironment when transplanted into ectopic sites in vivo [49] [50] [51] [52] . A number of studies have also reported the prospective isolation of a highly purified population of BMSC from murine compact bone [53] [54] [55] [56] , which express Sca-1 but lack expression of hematopoietic and endothelial cell lineage markers.
Human BMSC express high levels of EphB1, EphB2, EphB4, ephrin-B1 and ephrin-B2 (Table 1 ; Fig. 3 ), where Eph/ephrin interactions are known to regulate bone remodelling between stromal cells and osteoclasts [7, 8, 18, [57] [58] [59] [60] [61] . Forward signalling through EphB4 promotes BMSC osteogenic differentiation, whereas reverse signalling via ephrin-B2 suppresses osteoclast differentiation by inhibiting the c-Fos-NFATc1 signalling cascade. While EphB4/ephrin-B2 interactions promote bone formation, other reports have shown that EphA2/ephrin-A2 bidirectional signalling appears to regulate bone remodelling at the initiation phase, particularly enhancing bone resorption [57] . Reverse signalling through ephrin-A2, expressed in early differentiating osteoclasts, enhanced osteoclastogenesis, most likely mediated by activation of phospholipase Cγ2, whereas forward signalling through osteoblast-derived EphA2 suppressed osteoblastic bone formation and mineralization via activation of RhoA. The differences of bone resorption versus bone formation mediated by EphA2 and EphB4, respectively, could possibly due to the diversity of signalling activities. Forward signalling through EphA2 enhances RhoA activity resulting in inhibition of osteoblast differentiation, whereas signalling 
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Enhanced bone fracture repair [7] EphB4 Enhanced stromal support of hematopoiesis [44] EphB4 Protected subchondral bone and cartilage during osteoarthritis [82] Ephrin-B1 Loss of ephrin-B1 reduced bone formation [60] Ephrin-B2 Interactions with PTH and PTHrP in bone formation process [58, 67] Fig. 3 Human BMSC expression of EphB and ephrin-B molecules. Immunocytochemical staining of EphB/ephrin-B proteins (green) expressed by human ex vivo expanded BMSC, the cytoskeleton is defined by F-actin (red) staining, while the nucleus was stained with DPAI (blue), demonstrating the distribution of protein expression at the filapodia/lamelapodia and cytoskeleton. Scale Bar 20 µm via EphB4 suppresses RhoA activity and, therefore, stimulates osteoblast differentiation [18, 57, 59] . However, it is still unclear how EphA2 and EphB4 differentially regulate RhoA activity. Eph/ephrin signalling appears to be highly complex and often results in diametrically opposing responses in cell adhesion/repulsion, proliferation, migration, apoptosis and tumour promotion/suppression [13, 62, 63] . These cellular responses are thought to be dependent on cell type, differentiation state, tissue type, and the affinity of the Eph/ephrin pairings, which exhibit a high degree of promiscuity within and between the A and B subclasses.
Other molecules such as ephrin-B1 have been shown to be important for human BMSC maintenance and differentiation [8, 61, [64] [65] [66] . Loss-of-function mutations in ephrin-B1 disturb tissue boundary formation at the developing coronal suture, resulting in shortening of the skull, a condition known as craniofrontonasal syndrome and other skeletal deformities [60, 61] . Another ephrin-B ligand, ephrin-B2, expressed at lower levels in stromal cells, is regulated following activation of parathyroid hormone receptor 1 (PTHR1) in the presence of PTH, in a dose-dependent fashion, indicating a possible role for ephrin-B2 in the anabolic bone function of PTH [58, 67] . Collectively, these studies implicate different Eph/ephrin molecules in bone development/homeostasis, and stromal cell growth/differentiation, which are likely to have major consequences on the composition and function of the bone marrow HSC niche.
EphB/ephrin-B mediated interactions between BMSC and HSC
While a number of Eph/ephrin molecules have been identified on BMSC and HSC populations, the majority of studies have predominantly focused on the EphB4/ephrin-B2 interacting pair. Several studies have shown that EphB4 and ephrin-B2 regulate BMSC support of hematopoietic progenitor cells during erythropoiesis [23, 24, 27] . EphB4 expression has been detected on HSC isolated from human umbilical cord blood [23, 27] , while ephrin-B2, the cognate ligand of EphB4, was found to be expressed on BMSC [21, 44] . In this context, EphB4/ephrin-B2 interactions resulted in an increased incidence of human cord blood CD34 + /c-kit
+ HSC differentiation towards erythroid progenitor cells, correlating with the increased expression of glycophorin-A [23] . It was further confirmed that the interaction between EphB4 and ephrin-B2 during erythropoiesis was mediated through EphB4 forward signalling in cord blood CD34 + HSC [24] . Interestingly, EphB4 expression in HSC declined significantly after contact with an ephrin-B2 expressing stromal cell line [24] . These findings suggest that EphB4/ephrin-B2 interactions induced forward signalling within the EphB4 + HSC, which triggered the detachment of the EphB4 + HSC from the ephrin-B2 expressing stromal cell layer. This detachment was proposed to increase exposure to soluble cytokines such as erythropoietin, leading to the differentiation of HSC into mature erythroid cell, implying that forward rather than bidirectional or reverse signalling was essential for the process of stromal cell support of erythropoiesis. Conversely, EphB4 expressed by stromal cells modulates ephrin-B2 expression levels and subsequently affects transmigration of hematopoietic progenitor cells [21] . This study reported that ephrin-B2 expression levels by hematopoietic progenitor cells were significantly higher when co-cultured with EphB4
+ compared with EphB4 − stromal cells, indicating that EphB4 expressing stromal cells play a role in inducing ephrin-B2 expression by hematopoietic progenitor cells. Of note, ectopic expression of ephrin-B2 in the hematopoietic cell line, 70z/3, confirmed a significant decrease in the locomotive activity of hematopoietic cells underneath a stromal cell layer [21] . Moreover, disruption of EphB4/ephrin-B2 communication using an EphB4 peptide inhibitor or shRNA-mediated knockdown of EphB4 in BMSC reduced their capacity to support hematopoiesis in vitro [44] . In agreement with these findings, mouse BMSC derived from a transgenic EphB4 mouse model (EphB4Tg), under the control of the collagen type 1 promoter, exhibited an enhanced capacity to support HSC maintenance [44, 59] . The EphB4Tg mice exhibited a higher frequency of BMSC lineage cells including osteoprogenitors and osteoblasts, correlating with an increased clonogenicity of BMSC. Moreover, EphB4 over-expressing BMSC influenced the hematopoietic progenitor/stem cell compartment, resulting in a significant increase of hematopoietic stem/progenitor cell numbers both in vitro and in vivo [44] . Assessment of hematopoietic reconstitution following bone marrow ablation found that donor HSC, infused into irradiated mice, demonstrated increased levels of homing to the bone marrow and engraftment in recipient EphB4Tg mice compared to wild type littermates. Collectively, these findings imply that EphB4-ephrin-B2 interactions are important mediators of the HSC niche microenvironment. The molecular basis of the increased support of ephrin-B2 expressing HSC by EphB4 overexpressing BMSC was attributed, in part, to increased gene and protein expression levels of hematopoietic supportive factors such as CXCL12, Angiopoietin-1, IL-6, FLT-3 ligand and Osteopontin by EphB4 overexpressing BMSC [44] , where CXCL12 has also been widely described as a key mechanism in HSC homing [68, 69] . Whilst further studies are required to determine the downstream signalling events mediating EphB4/ephrin-B2 BMSC-HSC communication, these findings have identified an important role for EphB/ ephrin-B in BMSC-mediated support of hematopoiesis, offering potential new insights into the environmental factors essential for the regulation of HSC by BMSC.
EphA/ephrin-A interactions between BMSC and HSC
The consequences of EphA/ephrin-A signalling during BMSC-HSC communications remain less explored than their EphB/ephrin-B counterparts due to the scarcity of knowledge on GPI-linked ephrin-A ligands which lack a cytoplasmic signalling domain [13, 70] . Recently, the A subclass of Eph and ephrin molecules have been reported to influence the migration of hematopoietic progenitor cells, where ephrin-A5 enhanced HSC trafficking and adhesion patterns [26] . EphA3-mediated reverse signalling through ephrin-A5 influenced HSC adhesion via the VLA-4 ligand, integrin α 4 β 1 molecule (CD49d/CD29) to the extracellular matrix protein ligand, fibronectin and the immunoglobular superfamily member ligand, vascular cell adhesion molecule-1 (CD106) [26] , known to be highly expressed by purified human BMSC prior to culture [45] . Indeed, the activation of ephrin-A5 signalling within HSC resulted in the phosphorylation of paxillin, a downstream effector of integrin function [26] . Integrins are proteins that mediate cell-cell and cell-matrix attachment within a tissue; their function is critical for HSC adhesion, proliferation and migration during hematopoietic development [71] . Moreover, HSC adhesion to BMSC has been reported to occur through integrin α 4 β 1 /CD106-dependent mechanisms [72] . Therefore, activation of ephrin-A5 by EphA3 affected HSC adhesion through an integrin-mediated mechanism. Interestingly, an intraperitoneal injection of EphA3-fusion protein into mice enhanced the mobilization of HSC into the peripheral blood, whereas blocking EphA3/ephrin-A5 interactions by functional blocking peptides affected the in vivo homing properties of HSC [26] . Hence, ephrin-A reverse signalling plays a potential role in modifying the adhesive properties of HSC within the bone marrow niche via an integrin-mediated mechanism where activation of ephrin-A promoted HSC migration to the peripheral blood and inhibited HSC homing to their niche. These observations suggest a potential role for EphA/ephrin-A communication between HSC and BMSC. While these findings are compelling, it must be noted that ephrin-A5 is also known to interact with EphB2 [73] , expressed by both murine and human BMSC [8, 59] . Therefore, there may be a considerable diversity in the signalling activities mediated via ephrin-A5, where the involvement of EphB2/ephrin-A5 interactions in HSC maintenance remains to be demonstrated. Nevertheless, these findings have identified EphA/ephrin-A signalling as one potential mechanism regulating the migration of HSC within the hematopoietic microenvironment. Given that HSC reside in close proximity to BMSC within the bone marrow microenvironment [74] , EphA/ephrin-A interactions may act as important mediators of cross-talk between BMSC and primitive HSC to maintain the stem cell pool and regulate blood cell production.
Targeting Eph/ephrin interactions as therapeutic strategies for haematological malignancies
The central role of Eph/ephrin signalling mechanisms in hematopoietic development and homeostasis has triggered mounting interest in exploring their role in a number of haematological conditions. The potential role of EphA/ ephrin-A signalling has recently been recognized in haematological malignancies including acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myelodysplastic syndromes and myeloproliferative disorders [75] [76] [77] . The EphA3 receptor is highly expressed within the bone marrow microenvironment of human leukemia and mouse tumour xenografts; however, its expression is not detectable in the non-malignant microenvironment. This significant finding prompted the development of the agonistic anti-EphA3 antibody, mAb IIIA4, as an anti-cancer therapeutic. The IIIA4 mAb has been shown to trigger EphA3 activation leading to inhibition of tumour growth by disrupting the integrity and function of newly formed tumour stroma and microvasculature, resulting in tumour cell contraction, aggregation and apoptosis [75] . Further therapeutic development has resulted in a recombinant, defucosylated human immunoglobulin G1k (IgG1k) therapeutic mAb version (KB004; KaloBios Pharmaceuticals, California, USA) [78] . The KB004 antibody has displayed anti-tumour activity by targeting EphA3
+ tumour stroma and vasculature to induce leukemic stem cell apoptosis. An ongoing phase I clinical trial over multiple centres is currently examining the clinical efficacy and safety of KB004 in treating various haematological diseases (ClinicalTrials.gov identifier number NCT01211691).
While anti-cancer agents targeting EphA/ephrin-A signalling in leukemia is in clinical trials, the role of EphB4 in multiple myeloma (MM) has also been investigated [79, 80] . The haematological disease MM is a plasma cell malignancy caused by an elevated bone resorption by osteoclasts and reduced bone formation by osteoblasts, resulting in osteolytic lesions, fractures and hypercalcemia [81] . While EphB4/ephrin-B2 signalling between osteoblasts and osteoclasts is important for bone homeostasis [59] , bone fracture repair [7] and osteoarthritis [82] , EphB4 expression in myelomatous bones is diminished compared with healthy counterparts [80] . In an attempt to manipulate the EphB4/ephrin-B2 signalling in MM microenvironment, it was shown that EphB4-fusion protein (EphB4-Fc) treatments in the humanised SCID (SCID-Hu) mouse model of MM resulted in an enhanced osteoblast number and subsequently bone formation while a reduction in osteoclast number was observed [80] . These findings are in agreement with that of Zhao et al. 2006 who demonstrated that EphB4/ephrin-B2 signalling is a critical mechanism for bone homeostasis [59] . Perhaps, MM cells-mediated downregulation of EphB4 expression in osteogenic cells may facilitate osteolytic disease via reduced bone formation and increased bone resorption through activation of osteoclasts. In support of this notion, EphB4-Fc treatment in MM of SCID-Hu mice showed a reduction in tumour burden. Most significantly, the anti-myeloma activity of EphB4 was not acting on MM cells but on human BMSC, confirming a MM cell-mediated imbalance of ephrin-B2/EphB4 signalling in the BMSC population. It is postulated that EphB4-Fc exerts its modulatory effects on the bone marrow microenvironment of MM by inhibiting osteoclastogenesis and neovascularization, while promoting osteoblast activity. These findings may lead to a therapeutic approach to upregulate the endogenous expression of EphB4 in MM bone marrow microenvironment, perhaps by administration EphB4-Fc to suppress tumour burden and restore the balance of the bone coupling process in MM patients.
Concluding remarks
The significant role facilitated by the Eph and ephrin molecules in mediating BMSC support of hematopoietic progenitor and stem cells has raised the importance of Eph/ephrin in the regulation of the hematopoietic system under normal and malignant circumstances. A number of Eph and ephrin HPC hematopoietic progenitor cells, CXCL12 C-X-C motif chemokine 12, also known as stromal cell-derived factor 1, Ang-1 angiopoietin-1, IL-6 interleukin-6, LSC leukemic stem cell molecules have been reported as potential mediators (Fig. 4) . However, BMSC and hematopoietic populations express a wide range of Eph/ephrin molecules and interacting partners owing to the large number of possible Eph/ephrin interactions due to their promiscuous binding nature; the impact mediated by Eph/ephrin molecules may vary for different situations. Therefore, further analyses are required to gain a more comprehensive understanding of the functional role of individual Eph/ephrin molecule pairs used for communication between different BMSC-hematopoietic populations. Increased knowledge of these processes may lead to the development of therapeutic strategies that enhance HSC mobilization, homing and engraftment. Similarly, EphA3 expression within the bone marrow microenvironment may be exploited to disrupt the maintenance of localized leukemic stem cells (LSC). With increasing focus on targeting EphA3 as a promising anti-cancer therapy, further investigations into the underlying mechanisms of EphA3 action would be desirable. Similarly, MMmediated downregulation of EphB4 expression in BMSC appears to be a contributing factor to the severity of osteolytic disease and tumour burden. This significant finding may have therapeutic potential and further research would provide a better understanding of EphB4 involvement in MM. Collectively, these studies pave the way for targeting Eph/ephrin signalling involved in regulation of the HSC microenvironment, in order to influence clinical outcomes for various haematological malignancies and associated disorders.
